Claims
- 1. A polypeptide selected from the group comprising polypeptide Iα [SEQ ID NO:1], polypeptide Iβ [SEQ ID NO:3], and polypeptide Io [SEQ ID NO:4].
- 2. The polypeptide of claim 1, wherein said polypeptide is linked covalently to an affinity chromatography matrix.
- 3. The polypeptide of claim 2, wherein said affinity chromatography matrix is sepharose, agarose, polyacrylamide, or cellulose.
- 4. A method for identifying a CFTR-binding compound comprising contacting a putative CFTR-binding compound with polypeptide Iα [SEQ ID NO:1] under conditions sufficient to allow for binding of said putative CFTR-binding compound to said polypeptide Iα, and determining whether such binding occurred, an indication that said putative CFTR-binding compound is a CFTR-binding compound.
- 5. The method of claim 4, wherein said CFTR-binding compound has a neutral or negative-affinity for polypeptide Iβ [SEQ ID NO:3] or polypeptide Io [SEQ ID NO:4].
- 6. The method of claim 4, wherein said CFTR-binding compound causes the aggregation of liposomes when added to a composition comprising said liposomes.
- 7. The method of claim 4, wherein said CFTR-binding compound causes the aggregation of chromaffin granules when added to a composition comprising said chromaffin granules.
- 8. The method of claim 7, wherein said composition consists essentially of said chromaffin granules in 1 mM CaCl2.
- 9. A method of treating cystic fibrosis in a mammal in need of such treatment, comprising administering a therapeutically effective amount of a compound having the formula
- 10. The method of claim 9, wherein R1 and R3 are methyl, propyl, or allyl, R7 is methyl or hydrogen, and R8 is cyclopentyl or cyclohexyl.
- 11. The method of claim 9, wherein said mammal is a human.
- 12. The method of claim 11, wherein said compound is selected from the group consisting of 1,3-dipropyl-7-methyl-8-cyclopentylxanthine, 1,3-dipropyl-7-methyl-8-cyclohexylxanthine, 1,3-diallyl-8-cyclohexylxanthine, and 8-cyclohexyl caffeine.
- 13. The method of claim 12, wherein said compound is 1,3-diallyl-8-cyclohexylxanthine.
- 14. The method of claim 9, wherein said compound is administered to the lung of said human.
- 15. The method of claim 14, wherein said compound is administered as an aqueous pharmaceutical composition containing from about 0.001 to about 0.01% w/w of said compound.
- 16. The method of claim 9, wherein said Ki is at least 0.05.
- 17. A compound having the formula
- 18. The compound of claim 17, wherein said compound is 1,3-diallyl-8-cyclohexylxanthine.
- 19. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound having the formula
- 20. The pharmaceutical composition of claim 19, wherein said compound is 1,3-diallyl-8-cyclohexylxanthine.
- 21. A polynucleotide selected from the group consisting of polynucleotide Iα [SEQ ID NO:2], polynucleotide Iβ [SEQ ID NO:5], and polynucleotide Io [SEQ ID NO:6].
CROSS-REFERENCE TO RELATED APPLICATION
[0001] This is a continuation-in-part of copending application Ser. No. 07/952,965, filed Sep. 29, 1992, now U.S. Pat. No. 5,366,977.
Divisions (2)
|
Number |
Date |
Country |
Parent |
09114537 |
Jul 1998 |
US |
Child |
09580458 |
May 2000 |
US |
Parent |
08343714 |
Nov 1994 |
US |
Child |
09114537 |
Jul 1998 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
09580458 |
May 2000 |
US |
Child |
10188047 |
Jul 2002 |
US |